QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:OPNT

Opiant Pharmaceuticals - OPNT Stock Forecast, Price & News

$20.16
-0.06 (-0.30%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.16
$20.25
50-Day Range
$9.38
$20.22
52-Week Range
$7.34
$37.71
Volume
49,094 shs
Average Volume
64,372 shs
Market Capitalization
$104.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00

Opiant Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
108.3% Upside
$42.00 Price Target
Short Interest
Healthy
0.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.10) to ($3.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

758th out of 1,023 stocks

Pharmaceutical Preparations Industry

369th out of 501 stocks

OPNT stock logo

About Opiant Pharmaceuticals (NASDAQ:OPNT) Stock

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

Indivior To Buy Opiant For $145 Mln In Cash
Indivior PLC to Acquire Opiant Pharmaceuticals
See More Headlines
Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Company Calendar

Last Earnings
11/14/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPNT
Employees
37
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$42.00
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+108.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%

Debt

Sales & Book Value

Annual Sales
$47.78 million
Cash Flow
$0.83 per share
Book Value
$9.92 per share

Miscellaneous

Free Float
3,865,000
Market Cap
$104.11 million
Optionable
Not Optionable
Beta
0.83

Social Links


Key Executives

  • Dr. Roger Crystal M.D.Dr. Roger Crystal M.D. (Age 46)
    Pres, CEO & Director
    Comp: $1.01M
  • Mr. David D. O'Toole (Age 63)
    Chief Financial Officer
    Comp: $624.74k
  • Dr. Phillip Skolnick D.Sc. (hon) (Age 75)
    Ph.D., Chief Scientific Officer
    Comp: $638.17k
  • Mr. Ben Atkins
    VP of Communications & Investor Relations
  • Mr. Brian Gorman
    EVP Corp. Devel. & Gen. Counsel
  • Dr. Mark Heath Ellison Ph.D.
    Chief Devel. Officer
  • Mr. Matthew R. RuthMr. Matthew R. Ruth (Age 52)
    Chief Commercial Officer













OPNT Stock - Frequently Asked Questions

Should I buy or sell Opiant Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OPNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPNT, but not buy additional shares or sell existing shares.
View OPNT analyst ratings
or view top-rated stocks.

What is Opiant Pharmaceuticals' stock price forecast for 2023?

3 Wall Street research analysts have issued twelve-month price objectives for Opiant Pharmaceuticals' shares. Their OPNT share price forecasts range from $42.00 to $42.00. On average, they expect the company's share price to reach $42.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price.
View analysts price targets for OPNT
or view top-rated stocks among Wall Street analysts.

How have OPNT shares performed in 2022?

Opiant Pharmaceuticals' stock was trading at $33.63 at the beginning of the year. Since then, OPNT stock has decreased by 40.1% and is now trading at $20.16.
View the best growth stocks for 2022 here
.

When is Opiant Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our OPNT earnings forecast
.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its earnings results on Monday, November, 14th. The technology company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.51) by $0.42. The technology company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $4.43 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%.

What other stocks do shareholders of Opiant Pharmaceuticals own?
What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Who are Opiant Pharmaceuticals' major shareholders?

Opiant Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.43%), Dimensional Fund Advisors LP (2.18%), Parkman Healthcare Partners LLC (1.48%), Essex Investment Management Co. LLC (0.91%), Two Sigma Advisers LP (0.45%) and Two Sigma Investments LP (0.42%). Insiders that own company stock include Ann L Macdougall, Brian Gorman, Craig A Collard, Craig A Collard, David D O'toole, Gabrielle Alison Silver, Matthew R Ruth, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas.
View institutional ownership trends
.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $20.16.

How much money does Opiant Pharmaceuticals make?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a market capitalization of $104.11 million and generates $47.78 million in revenue each year. The technology company earns $3.01 million in net income (profit) each year or ($6.56) on an earnings per share basis.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The official website for the company is www.opiant.com. The technology company can be reached via phone at (310) 598-5410, via email at investor.relations@opiant.com, or via fax at 917-322-2105.

This page (NASDAQ:OPNT) was last updated on 12/6/2022 by MarketBeat.com Staff